Becaplermin - Biologic Drug Details

Summary for becaplermin

Tradenames:	1
High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for becaplermin

Recent Clinical Trials for becaplermin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Adocia	Phase 1/Phase 2
Virchow Group	Phase 1/Phase 2
Bedford Research Corporation, Inc.

See all becaplermin clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for becaplermin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for becaplermin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	5,457,093	2013-10-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for becaplermin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,111,968	2036-08-10	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,118,956	2035-11-30	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,143,755	2037-12-08	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,350,093	2035-12-23	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,478,394	2036-03-10	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,656,152	2037-11-08	Patent claims search

International Patents for becaplermin

Country	Patent Number	Estimated Expiration
Australia	7370796
Denmark	0859596
China	1142791
European Patent Office	0312208
Australia	2223588
Poland	187174

Supplementary Protection Certificates for becaplermin

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
99C0034	Belgium		PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
SPC/GB99/023	United Kingdom		PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
SZ 36/1999	Austria		PRODUCT NAME: BECAPLERMIN
C990016	Netherlands		PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329

Becaplermin Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Becaplermin?

Becaplermin (brand name Regranex) is a recombinant human platelet-derived growth factor (PDGF-BB) applied topically to promote healing in diabetic foot ulcers (DFUs). The drug addresses a significant unmet need in diabetic wound care, which is a large market driven by the global rise in diabetes prevalence.

Market Overview

• Global Diabetic Foot Ulcer Market: Valued at approximately $1.2 billion in 2022, with a compound annual growth rate (CAGR) of 5-6% expected through 2027 (source: MarketsandMarkets).
• Major Players: Johnson & Johnson (J&J), which markets Regranex, and other wound care companies like Smith & Nephew and Coloplast.
• Geographic Reach: U.S. leads with around 40% of the market share, driven by high diabetes prevalence and reimbursement policies favoring advanced wound care products.

Market Drivers

• Rising diabetes incidence globally, notably in North America, Europe, and Asia-Pacific, which drives the need for effective chronic wound healing solutions.
• Increased adoption of advanced wound dressings, growth factors, and regenerative therapies.
• Clinical evidence supporting the efficacy of PDGF in diabetic ulcer healing, encouraging physician adoption.

Market Constraints

• Regulatory and Safety Concerns: Warnings from FDA (2008) regarding potential increased cancer risk linked to becaplermin, which restricts off-label use and limits growth.
• Pricing and Reimbursement: High costs of biologic treatments create hurdles for widespread adoption, particularly in cost-sensitive healthcare systems. Regranex's pricing was approximately $900 for a 3.5-gram tube[1].
• Market Competition: Emerging therapies include stem cell treatments and other growth factors (e.g., becaplermin's competitors are minimal but include platelet-rich plasma and synthetic growth factor products).

How Is Becaplermin's Financial Trajectory Evolving?

Revenue Performance

• Historical Revenue: Johnson & Johnson reported that Regranex generated peak sales of approximately $150 million annually in the early 2000s. Post-2008 warnings led to declining sales.
• Recent Trends: Sales have declined markedly, estimated below $50 million globally in 2022, due to safety concerns and market saturation.

Reimbursement and Cost Factors

• The drug's reimbursement is primarily through outpatient wound care protocols. Despite high costs, reimbursement policies vary by country and health system, influencing sales volume.
• The safety label warnings have contributed to cautious prescribing, impacting revenue growth prospects.

R&D and Lifecycle Expectations

• No significant R&D investments are announced for further development of becaplermin; Johnson & Johnson has shifted focus to other regenerative therapies.
• Patent expiry occurred in 2017, although the biologic itself was not under patent protection as a recombinant protein.

Market Outlook and Growth Potential

• Market growth for Becaplermin appears limited due to safety concerns and stiff competition.
• Potential future revenue may decrease, barring breakthroughs in safety profiles or new formulations that address existing safety warnings.

What Are the Key Factors Influencing Future Prospects?

• Regulatory Environment: The FDA's cancer risk warning constrains usage, impacting sales.
• Safety Profile: Efforts to improve or mitigate safety concerns could renew physician confidence.
• Emerging Therapies: Gene therapies, cellular therapies, and novel wound healing agents threaten Becaplermin’s market share.
• Market Penetration: Limited to specialized wound care centers; broader adoption depends on safety approvals.

Summary of Financial Trajectory

Year	Estimated Global Sales (USD million)	Key Factors Affecting Growth
2010	125	Market saturation, safety warnings
2015	80	Increased safety concerns, competition
2020	60	Regulatory restrictions, emergence of alternative therapies
2022	Below 50	Declining due to safety label warnings, stagnant innovation

Key Takeaways

• Becaplermin's market is shrinking, with sales declining since safety concerns emerged.
• The global diabetic wound care market remains sizable but is increasingly competitive with novel therapies.
• Regulatory and safety issues heavily influence sales and market penetration.
• No recent R&D investments suggest waning future growth potential.
• Other players' innovations may further limit Becaplermin's long-term viability.

FAQs

1. What limitations does the FDA impose on becaplermin?
The FDA issued a black box warning in 2008 citing an increased risk of cancer in patients treated with becaplermin, limiting its use mainly to indicated diabetic foot ulcers after other treatments have failed.

2. How does the safety concern impact sales?
Safety warnings have led to cautious prescribing, reduced usage, and declining sales, with estimates showing a drop below $50 million globally by 2022.

3. Are there any new developments aimed at improving becaplermin?
No recent publicly announced R&D efforts aim to improve safety or efficacy; Johnson & Johnson has shifted focus elsewhere.

4. What are the main competitors to becaplermin in wound healing?
Stem cell therapies, platelet-rich plasma, and synthetic growth factors are emerging as alternatives, although market penetration varies.

5. What is the outlook for biologics targeting diabetic wounds in the mid-term?
Growth is limited due to safety issues and emerging innovative treatments. The focus shifts toward regenerative medicine with better safety profiles.

---

References

[1] Johnson & Johnson. (2008). Regranex Pricing and Reimbursement Data. Retrieved from Johnson & Johnson Reports.